During its January 2024 meeting, the European Medicine Agency’s CHMP reviewed six recommendations for eligibility to PRIME. Two were granted and four were denied. Among the two granted eligibility was Sangamo’s isaralgagene civaparvovec for the treatment of Fabry disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
